Prospective randomized study of S-1 combined with oxaliplatin and docetaxel in the treatment of advanced gastric cancer

PAN Xianfeng; XU Yanhua; LONG Jian

doi:10.3969/j.issn.1671-6450.2014.10.008

Abstract：Objective To explore the short-term efficacy and safety of docetaxel combined with oxaliplatin or S-1 in the treatment of advanced gastric cancer .Methods Ninty cases of untreated patients with advanced gastric cancer were ran-domly divided into study group ( S-1 combined with oxaliplatin ) and control group ( S-1 combined with docetaxel ) ,45 cases in each group.The 2 groups were treated with S-1 capsule 40 mg/m2, bid, 3 weeks for one cycle.The study group’s first day’ s treatment were combined with oxaliplatin 130 mg/m2 intravenous drip, 3 weeks for one cycle;the control group’s first day’ s treatment were plus with docetaxel 60 mg/m2 intravenous drip, 3 weeks for 1 cycles.The 2 groups’ treatment was completed at least 2 cycles.Compared 2 groups’ recently, long-term efficacy, adverse reactions and quality of life after 2 cycle treat-ment.Results After 6 weeks treatment, the efficiency of study group and the control group ’ s were 55.6% and 46.6%(χ2 =0.71, P >0.05);disease control rate were 91.1% and 84.4% (χ2 =0.93, P >0.05).The study group and the control group’s mTTP were 6.1 and 4.7 months ( t =1.842, P =0.069); mOS were 11.4 and 12.3 months respectively (t =0.896, P =0.387);PFS were 8.3 and 7.6 months respectively ( t =1.273, P =0.206); OS were 11.6 and 10.4 months ( t =1.493, P =0.139).The study group and the control group ’s improvement of quality of life were 88.9% and 80.0%respectively (χ2 =1.35, P =0.245).The study group and control group ’s anemia were 46.7%and 26.7%(χ2 =3.88, P =0.048);hand foot syndrome were 17.8%and 40.0%respectively (χ2 =5.41, P =0.020);abnormal liver func-tion were 11.1%and 37.8%(χ2 =8.66, P =0.003).Conclusion S-1 combined with oxaliplatin or docetaxel , a consider-able effect of the two kinds of schemes , but S-1 combined with oxaliplatin has less adverse drug reaction .